

14 August 2023

## Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act

**Melodiol Global Health Limited (ASX:ME1, FRA:1X8) ('Melodiol' or 'the Company')** gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act").

The Company advises that it has issued ordinary fully paid shares in the capital of the Company, per the Appendix 2A lodged with the ASX today ("Shares"). The Shares were issued without disclosure to investors under Part 6D.2 of the Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Corporations Act.

As at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

**-Ends-**

### Authority and Contact Details

This announcement has been authorised for release by the Board of Melodiol Global Health Limited.

For further information, please contact:

### Investor Enquiries

Melodiol Global Health Limited

E: [info@melodiol-global-health.com](mailto:info@melodiol-global-health.com)

P: +61 (0) 497 571 532

### About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

### Melodiol offices:

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0